FDAnews
www.fdanews.com/articles/100912-cougar-biotechnology-presents-cb7630-data

Cougar Biotechnology Presents CB7630 Data

November 9, 2007

Cougar Biotechnology reported results from Phase II trials of its prostate cancer drug CB7630.

In the study, CB7630 (abiraterone acetate) was administered to patients with advanced prostate cancer who failed androgen deprivation and docetaxel-based chemotherapy. Forty-four patients have been enrolled in the trial.

Of the 10 patients who have been treated in the Phase II trial, CB7630 was well tolerated with only minimal toxicity. Four patients experienced a confirmed decline in prostate specific antigen levels of greater than 50 percent. Of the five patients with measurable tumor lesions, one experienced a partial radiological response, Cougar said.